Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 30INDUSTRY 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 5

Conditions

Carcinoma, Non-Small-Cell Lung 199Breast Neoplasms 136Prostatic Neoplasms 72Neoplasms 62Neoplasm Metastasis 52Lung Neoplasms 45Stomach Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 22Squamous Cell Carcinoma of Head and Neck 17Ovarian Neoplasms 15Advanced Solid Tumors 14Recurrence 12Head and Neck Neoplasms 11Colorectal Neoplasms 11Carcinoma, Squamous Cell 11Urinary Bladder Neoplasms 10Melanoma 10Esophageal Neoplasms 10HER2-positive Breast Cancer 9Endometrial Neoplasms 9Carcinoma, Renal Cell 9Sarcoma 8Esophageal Squamous Cell Carcinoma 8Carcinoma, Transitional Cell 8Solid Tumor 7Prostatic Neoplasms, Castration-Resistant 7Pancreatic Neoplasms 7Carcinoma 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 6

Interventions

Gemcitabine 12Cisplatin 11pembrolizumab 6Docetaxel 5Capecitabine 5camrelizumab 4Injections 4toripalimab 3spartalizumab 3penpulimab 2famitinib 2SHR-1701 2Carboplatin 218-O-demethylcervinomycin A2 2tislelizumab 1icotinib 1donafenib 1cc-486 1Valganciclovir 1Radiotherapy, Intensity-Modulated 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Medicare Part B 1Ipilimumab 1Immunotherapy 1Fluorouracil 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Nasopharyngeal Carcinoma × Docetaxel × Clear all
NCT06118333 2026-04-17

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
386 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Shanghai Miracogen Inc.

Phase 2 Active not recruiting
238 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06976190 2026-01-20

Magic-C002

Shanghai Miracogen Inc.

Phase 3 Recruiting
446 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06629597 2025-02-10

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 3 Recruiting
400 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT00565448 2015-07-30

Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents

Sanofi

Phase 2 Completed
75 enrolled 10 charts
Head & Neck

Nasopharyngeal Carcinoma, Carcinoma, Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡